News

Embecta raises adjusted EBITDA margin outlook for FY 2025 amid restructuring and debt reduction
Discover key insights from Embecta's Q2 2025 earnings call. Learn about revenue forecasts, cost-saving initiatives, product strategies & market dynamics.
Embecta Corp. (NASDAQ:EMBC) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript May 9, 2025 Embecta Corp. beats earnings expectations. Reported EPS is $0.7, expectations ...
Embecta Corp. (EMBC) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Conference Call May 9, 2025 8:00 AM ETCompany ParticipantsDev Kurdikar - President & CEOJake Elguicze ...
Injectable Drug Delivery Market worth US$1,034.78 billion by 2030 with 8.4% CAGR | MarketsandMarkets™
The global Injectable Drug Delivery Market, valued at US$633.7 billion in 2024, is forecasted to grow at a robust CAGR of 8.4 ...
Injectable Drug Delivery Market worth US$1,034.78 billion by 2030 with 8.4% CAGR | MarketsandMarkets
The global Injectable Drug Delivery Market, valued at US$633.7 billion in 2024, is forecasted to grow at a robust CAGR of 8.4%, reaching US$690.23 ...
Q2 2025 Embecta Corp Earnings Call
Welcome, ladies and gentlemen, to Embecta Corp's Fiscal Second Quarter 2025 Earnings Conference Call. (Operator Instructions) Please note that this conference call is being recorded and a replay will ...
Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results
Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month ...